Prospective ICH Q2(R2)-Aligned Total-Error Validation of Label-Free Untargeted Proteomics for Host Cell Protein Quantification in Biotherapeutics
Proteomes · 23.04.2026 · 14 (2) · 21
DOI: 10.3390/proteomes14020021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proteomes, online erschienen am 23.04.2026. Verfasst von Somar Khalil und 3 weiteren Autor:innen. Beteiligte Einrichtung: Technical Research & Development, GSK, 1330 Rixensart, Belgium. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Untargeted proteomics enables quantitative host cell protein (HCP) determination in biotherapeutics, yet no workflow has been validated under ICH Q2(R2) for regulated quality control.
Methods
A prospective total-error (TE) validation of label-free ddaPASEF proteomics was performed. A stable isotope-labeled whole-proteome standard was spiked into NISTmAb at seven levels (20–80 ng) and analyzed in four independent assays (198 injections), supporting one-way random-effects ANOVA with Welch–Satterthwaite adjustment. Peptide-level identification error was evaluated by dual entrapment.
Results
Empirical false-discovery proportions were below 1% at q = 0.01. Weighted least-squares regression (R2 = 0.993) confirmed stable proportional compression with 81–85% recovery. Repeatability dominated the variance structure (median CV 2.7%); intermediate precision SD ranged from 0.69% to 3.81%. Both 95% β-expectation and 95/95 content tolerance intervals were contained within ±30% at all levels, defining a validated range of 20–80 ng. Abundance-stratified TE profiling revealed concentration-dependent calibration heterogeneity, with stratum-specific intervals within ±35% defining an abundance-aware LLOQ of 3.6 ppm (P95 = 3.87 ppm). Robustness under independent search software (FragPipe v24.0, CCC = 0.998) and cross-platform acquisition (Astral, CCC = 0.980) remained within ±30% limits.
Conclusions
This constitutes the first prospective ICH Q2(R2)-aligned validation of untargeted proteomics for HCP quantification, with a transferable statistical framework for high-dimensional analytical methods.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Technical Research & Development, GSK, 1330 Rixensart, Belgium.
ORCID-Profile: Somar Khalil, Jean-François Dierick
Zitieren
APA
Khalil, S., Dierick, J. F., Bourguignon, P., & Plisnier, M. (2026). Prospective ICH Q2(R2)-Aligned Total-Error Validation of Label-Free Untargeted Proteomics for Host Cell Protein Quantification in Biotherapeutics. Proteomes, 14(2), 21. https://doi.org/10.3390/proteomes14020021
Vancouver
Khalil S, Dierick JF, Bourguignon P, Plisnier M. Prospective ICH Q2(R2)-Aligned Total-Error Validation of Label-Free Untargeted Proteomics for Host Cell Protein Quantification in Biotherapeutics. Proteomes. 2026;14(2):21. doi:10.3390/proteomes14020021
BibTeX
@article{Khalil2026,
author = {Khalil, Somar and Dierick, Jean-François and Bourguignon, Pascal and Plisnier, Michel},
title = {Prospective ICH Q2(R2)-Aligned Total-Error Validation of Label-Free Untargeted Proteomics for Host Cell Protein Quantification in Biotherapeutics},
journal = {Proteomes},
year = {2026},
volume = {14},
number = {2},
pages = {21},
doi = {10.3390/proteomes14020021}
}
EUVIMED